[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opus Genetics Inc (IRD)

Opus Genetics Inc (IRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 390,701
  • Shares Outstanding, K 81,396
  • Annual Sales, $ 14,200 K
  • Annual Income, $ -49,590 K
  • EBIT $ -39 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.62
  • Price/Sales 28.50
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 189.26% (-64.06%)
  • Historical Volatility 59.48%
  • IV Percentile 29%
  • IV Rank 11.46%
  • IV High 1,405.35% on 03/11/26
  • IV Low 31.89% on 09/16/25
  • Expected Move (DTE 32) 1.73 (36.13%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,903
  • Volume Avg (30-Day) 537
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 13,060
  • Open Int (30-Day) 13,272
  • Expected Range 3.07 to 6.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 6
  • High Estimate $-0.11
  • Low Estimate $-0.19
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.66 +3.00%
on 04/29/26
5.81 -17.38%
on 04/17/26
-0.91 (-15.94%)
since 04/15/26
3-Month
3.29 +45.90%
on 02/23/26
5.81 -17.38%
on 04/17/26
+1.16 (+31.87%)
since 02/13/26
52-Week
0.90 +432.68%
on 07/01/25
5.81 -17.38%
on 04/17/26
+3.85 (+405.26%)
since 05/15/25

Most Recent Stories

More News
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 4.80 (-3.42%)
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5...

IRD : 4.80 (-3.42%)
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and...

IRD : 4.80 (-3.42%)
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide...

IRD : 4.80 (-3.42%)
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 4.80 (-3.42%)
Opus Genetics to Participate in Leading Medical Conferences in May 2026

RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies...

IRD : 4.80 (-3.42%)
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 4.80 (-3.42%)
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment - - Strategic financing to accelerate development of earlier-stage...

IRD : 4.80 (-3.42%)
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing...

IRD : 4.80 (-3.42%)
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of...

IRD : 4.80 (-3.42%)

Business Summary

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills,...

See More

Key Turning Points

3rd Resistance Point 5.17
2nd Resistance Point 5.06
1st Resistance Point 4.93
Last Price 4.80
1st Support Level 4.68
2nd Support Level 4.56
3rd Support Level 4.43

See More

52-Week High 5.81
Last Price 4.80
Fibonacci 61.8% 3.93
Fibonacci 50% 3.36
Fibonacci 38.2% 2.78
52-Week Low 0.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.